Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 240

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 240
---
 ten-year period and are inherently less reliable
and subject to greater uncertainty with respect to periods further in the future, particularly in the later years. There is significant
risk that the Projections will deviate from actual results and the risk of such deviations are increased accordingly for later periods
covered by the Projections.

| 119 |

Board Consideration of
the Projections

As noted above,
the FutureTech Board reviewed and discussed the Projections in connection with its review of the Business Combination, and the Projections
were provided to Newbridge in connection with its delivery of its fairness opinion with respect to the transactions contemplated by the
Merger Agreement, which fairness opinion was considered by the FutureTech Board in its review of the Business Combination — please
see the “Opinion of Newbridge” section below for more information regarding the fairness opinion. As part of its evaluation
of the Projections, and the reasonableness thereof, the FutureTech Board considered the inherent risks of financial projections covering
extended periods of time and for product candidates that are subject to FDA approval. The FutureTech Board also evaluated the assumptions
made by Longevity’s management in preparing the Projections. Accordingly, while the FutureTech Board found the Projections to be
reasonable for the reasons outlined in the “Preparation of the Projections” section above, the FutureTech Board only
viewed the Projections as a potential indicator of future performance. The FutureTech Board also considered the discounted cash flow analysis
performed by Newbridge in connection with providing its fairness opinion, in which Newbridge applied, among other things, a discount risk
factor based on each product candidates’ clinical stage in order to account for the risk of receiving FDA approval. Accordingly,
FutureTech stockholders are strongly cautioned not to place undue reliance, if any, on the Projections in making any decisions regarding
the Business Combination. Further, the Projections were just one of many factors the FutureTech Board considered as part of their evaluation
of the proposed Business Combination, and the FutureTech Board did not consider the Projections as a determinative factor in entering
into the Merger Agreement. Please see the “The FutureTech Board’s Reasons for the Approval of the Business Combination”
section below for more information regarding the FutureTech Board’s reasons for the approval of the proposed Business Combination.

Further Considerations
for Stockholders

The inclusion
of financial projections in this proxy statement/prospectus should not be regarded as an indication that FutureTech, Longevity, their
respective